For many years, people diagnosed with a rare disease had little hope of treatment because the costs of research and development were so high for such small patient populations. But today, the outlook has shifted and there is a surge of life science companies prioritizing rare disease, like Mucopolysaccharidos I. Join experts and patient advocates to explore how and why the economic incentives have changed, the importance of patient advocacy to expedite research, and innovative approaches benefiting patients. And learn how these factors impact drug development, affordability and patient care.